Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Cencora (COR) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cencora is one of 949 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cencora is currently sporting a Zacks Rank of #2 (Buy).Within the past quarter, the Zacks Consensus Estimate for COR's full-year earnings has moved 1.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.Based on the latest available data, COR has gained about 61.2% so far this year. Meanwhile, stocks in the Medical group have gained about 4.8% on average. This shows that Cencora is outperforming its peers so far this year.Boston Scientific (BSX) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.2%.The consensus estimate for Boston Scientific's current year EPS has increased 2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Cencora belongs to the Medical Services industry, a group that includes 63 individual stocks and currently sits at #152 in the Zacks Industry Rank. On the other hand, Boston Scientific belongs to the Medical - Products industry. This 83-stock industry is currently ranked #160.Going forward, investors interested in Medical stocks should continue to pay close attention to Cencora and Boston Scientific as they could maintain their solid performance.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks